Business
Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results
Received approval for EMPAVELI™ (pegcetacoplan) – the first targeted C3 therapy – from U.S. Food and Drug Administration (FDA) for treatment of adults with
About this update from Apellis Pharmaceuticals, Inc.
[{"type":"text","content":"Received approval for EMPAVELI™ (pegcetacoplan) – the first targeted C3 therapy – from U.S. Food and Drug Administration (FDA) for treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) and launched in U.S.Reported positive top-line results from Phase 3 PRINCE study of EMPAVELI in treatment-naïve patients with PNHEstablished exclusive research collaboration with Beam Therapeutics to apply base editing to discover novel therapies for complement-driven diseasesExpect top-line results from Phase 3 geographic atrophy (GA) studies in September 2021Conference call scheduled today at 4:30 p.m. ET WALTHAM, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its second quarter 2021 financial results and business highlights. “The second quarter was an exceptional period for Apellis, underscored by the approval of EMPAVELI –– the first FDA-approved targeted C3 therapy –– for adults with PNH and a strong start to our U.S. commercial launch. We and our partner Sobi were also thrilled to report positive data from our Phase 3 PRINCE study in treatment-naïve PNH patients, emphasizing the potential for EMPAVELI to redefine treatment for all adults with PNH,” said Cedric Francois M.D., Ph.D., co-founder and chief executive officer of Apellis. “We are looking forward to the Phase 3 DERBY and OAKS readouts in September. GA is a leading cause of blindness worldwide, and we are excited about the potential to bring the first treatment to the millions of patients affected by this disease.” “In addition to the broad platform potential of our targeted C3 therapy, our world-class research team is advancing multiple new molecular entities across several modalities, and we entered an exclusive collaboration with Beam Therapeutics to discover transformative therapies using its base editing technology. With our expanded pipeline across rare disease, ophthalmology, and neurology, we believe we are well positioned for long-term, global leadership in complement,” Dr. Francois continued. Second Quarter 2021 Business Highlights and Upcoming Milestones: Rare Disease In May 2021, Apellis announced that the FDA approved EMPAVELI for the treatment of adults with PNH including patients who are treatment naïve, as well as patients switch...